TB-500 and Pulmonary Fibrosis Research: What the Lung Studies Show
TB-500's anti-fibrotic research is best known in the heart, liver, and kidney. A separate, more recent body of work looks at thymosin beta-4 in bleomycin-induced lung fibrosis — including a 2025 inhalation study and a complicated lung-cancer angle.
> Research disclaimer: This article reviews published preclinical research for informational and research purposes only. TB-500/Thymosin Beta-4 is not FDA-approved for any pulmonary or respiratory indication, is sold strictly as a research chemical, and nothing here is medical advice. Anyone with a lung condition should not substitute this article for guidance from a treating physician.
Quick answer: Thymosin beta-4's anti-fibrotic mechanism — already documented in our cardiac, liver, and kidney research articles — extends to a smaller, more recent literature on lung tissue. A 2025 study found that recombinant human thymosin beta-4 delivered by inhalation reduced fibrosis in the standard mouse bleomycin lung-injury model, working through the same TGF-β1 pathway implicated in the other organs. A related fragment, Ac-SDKP, has separately shown preventive and therapeutic effects in the same model. Almost none of this research used the injectable TB-500 fragment or a route resembling how TB-500 is typically discussed for research use — a distinction worth understanding before drawing conclusions.
One question this lung research doesn't answer, despite how often it comes up, is whether any of it applies to post-viral lung damage from COVID-19. It doesn't — the bleomycin and inhalation studies described below involve a chemotherapy-induced injury model, not viral illness, and no thymosin beta-4 study has examined long COVID or post-viral pulmonary recovery specifically. See our TB-500 and long COVID research guide for why that question keeps surfacing and why it points to a different peptide's research entirely.
Why Lung Fibrosis Is Its Own Research Question
Pulmonary fibrosis — progressive scarring of lung tissue that stiffens the lungs and impairs gas exchange — shares a basic mechanism with the fibrosis discussed elsewhere on this site: fibroblasts overproduce collagen, TGF-β signaling drives the process, and functional tissue is gradually replaced by disorganized scar. But the lung is structurally unlike the heart, liver, or kidney. Gas exchange happens across an extremely thin epithelial-capillary interface, and even modest scarring in that interface has an outsized effect on function. Idiopathic pulmonary fibrosis (IPF), the most severe form in humans, has a prognosis worse than many cancers and very few effective treatments. That combination — a devastating disease and a thin treatment pipeline — is why any anti-fibrotic mechanism draws research interest here, independent of what's already been shown in other organs.
The Bleomycin Model: How This Research Gets Done
Nearly all of the lung fibrosis research on thymosin beta-4 uses the bleomycin model, the standard method for studying pulmonary fibrosis in rodents. Bleomycin, a chemotherapy drug with a known side effect of causing lung fibrosis in humans, is administered to mice (usually intratracheally) to induce a fibrotic injury that mimics key features of the human disease. Researchers then measure outcomes like histological fibrosis scoring, collagen content in lung tissue, and markers of fibroblast activation to evaluate whether a candidate compound slows or reverses the process.
Key Finding: Inhaled Thymosin Beta-4 and Bleomycin-Induced Fibrosis
A 2025 study published in the Journal of Pharmacy and Pharmacology tested recombinant human thymosin beta-4 (rhTβ4) delivered by nebulization — an inhaled aerosol, not an injection — in mice with bleomycin-induced pulmonary fibrosis. The study found that aerosolized rhTβ4 reduced fibrosis at multiple stages of disease progression, not just when given early. In vitro work accompanying the study showed rhTβ4 suppressed lung fibroblast proliferation, migration, and activation, and inhibited an epithelial-mesenchymal transition-like process in pulmonary epithelial cells — a process where lung epithelial cells take on fibroblast-like, scar-producing characteristics. Both effects were tied to regulation of the TGF-β1 signaling pathway, the same pathway implicated in Tβ4's anti-fibrotic activity in cardiac and renal tissue.
A Related but Distinct Molecule: Ac-SDKP
A separate line of research examined Ac-SDKP, a naturally occurring N-terminal fragment of thymosin beta-4 (distinct from the 17-23 fragment that TB-500 itself represents). In the bleomycin model, Ac-SDKP showed both preventive effects — reducing fibrosis when given before injury — and therapeutic effects when administered after injury, with reduced histological fibrosis scores and collagen content measured out to 21 days. This is a useful reminder that thymosin beta-4 is a source molecule for multiple distinct peptide fragments with potentially different research profiles, and that "thymosin beta-4 research" isn't a single monolithic body of evidence — it spans the full-length peptide, Ac-SDKP, and TB-500's own fragment, each studied somewhat separately.
Inflammation and Oxidative Stress: A Second Injury Model
A different study used lipopolysaccharide (LPS) rather than bleomycin to induce murine lung fibrosis, finding that thymosin beta-4 attenuated oxidative injury and reduced inflammation in that model as well. Using a second, mechanistically different injury model (LPS triggers an acute inflammatory cascade rather than bleomycin's direct fibrotic stimulus) and finding a similar anti-fibrotic, anti-inflammatory result adds some consistency to the overall picture, even though both remain short-term rodent studies.
The IPF–Lung Cancer Study: A More Complicated Angle
One study examined thymosin beta-4 in a mouse model combining idiopathic pulmonary fibrosis with lung cancer — a clinically relevant pairing, since IPF patients have meaningfully elevated lung cancer risk. That study found exogenous Tβ4 suppressed IPF-associated lung cancer growth in mice, an effect the researchers linked to inhibition of the JAK2/STAT3 signaling pathway. This is worth flagging precisely because it cuts against the angiogenesis-driven cancer caution discussed in our side effects and safety guide: in this specific fibrosis-cancer comorbidity model, Tβ4 was associated with suppressed rather than promoted tumor growth. That doesn't resolve the broader theoretical cancer question — a single mouse model in one cancer context doesn't override a mechanistic caution grounded in angiogenesis biology — but it illustrates how context-dependent thymosin beta-4's cancer-related effects appear to be across different tissue and disease settings.
Route of Administration Is Not a Minor Detail
Nearly every study discussed here used inhaled or nebulized recombinant human Tβ4, not a subcutaneous injection of the TB-500 fragment. This matters for two reasons: first, inhaled delivery targets the drug directly to lung tissue in a way injectable administration would not replicate; second, most of what's discussed elsewhere on this site about TB-500 dosing, reconstitution, and injection protocol — see the reconstitution and dosing guide — has no bearing on how these lung studies were conducted. Anyone trying to map this research onto a typical injectable TB-500 protocol is extrapolating across both a different route of administration and, in some cases, a different molecule (full-length Tβ4 or Ac-SDKP rather than the TB-500 fragment).
What's Genuinely Unknown
Frequently Asked Questions
Has TB-500 (the injectable fragment) been studied for lung fibrosis?
No. The pulmonary fibrosis research reviewed here used inhaled recombinant full-length thymosin beta-4 or the Ac-SDKP fragment, delivered by nebulization in mice — not the injectable TB-500 fragment used in typical research protocols discussed elsewhere on this site.
Is pulmonary fibrosis research part of TB-500's broader anti-fibrotic profile?
Mechanistically, yes — it involves the same TGF-β1 pathway implicated in the cardiac, liver, and kidney fibrosis research. But it's a separate, smaller, and more recent literature, conducted with a different molecule and route of administration than most of TB-500's other research.
Does this research mean TB-500 could help idiopathic pulmonary fibrosis in humans?
That hasn't been tested. All of the lung fibrosis research to date is preclinical, conducted in mice using the bleomycin or LPS injury models. No human IPF trial of thymosin beta-4 exists.
Does the lung cancer study contradict TB-500's theoretical cancer-risk caution?
Not exactly — it adds nuance rather than contradicting it. In one specific IPF-associated lung cancer mouse model, Tβ4 was linked to suppressed tumor growth via a different pathway (JAK2/STAT3) than the angiogenesis mechanism behind the general cancer caution. Cancer-related effects appear to vary by tissue and disease context rather than pointing in one consistent direction.
What's the difference between Ac-SDKP and TB-500?
Both are fragments derived from the same parent molecule, thymosin beta-4, but they're different sequences with potentially different biological activity. TB-500 corresponds to the 17-23 region; Ac-SDKP is a separate N-terminal fragment studied mostly for anti-fibrotic effects. Research findings on one shouldn't be assumed to apply directly to the other.
Sourcing Quality Research Peptides
Fibrosis research protocols depend on knowing precisely what compound and concentration is being administered — a mislabeled or impure vial makes any anti-fibrotic finding uninterpretable. Apollo Peptide Sciences publishes batch-specific certificates of analysis with HPLC and mass spec data for its TB-500.
---
Related: TB-500 Cardiac Research · TB-500 and Liver Regeneration/Fibrosis Research · TB-500 and Kidney Research · TB-500 Scar Tissue and Fibrosis Research